Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

IVA

Inventiva ADR

Dec 11 • 04:00PM ET

2.53

Dollar change -0.06
Percentage change -2.31	%

Healthcare • Biotechnology • France • NASD

Peers: BMRN VRTX CRSP EDIT PFE NTLA SGMO ABBV GILD NBIX

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.23	Insider Own	1.68%	Shs Outstand	86.90M	Perf Week	-3.43%
Market Cap	219.87M	Forward P/E	-	EPS next Y	-1.19	Insider Trans	0.00%	Shs Float	85.44M	Perf Month	-6.29%
Income	-112.65M	PEG	-	EPS next Q	-0.61	Inst Own	3.90%	Short Float	0.41%	Perf Quarter	12.45%
Sales	16.89M	P/S	13.02	EPS this Y	33.87%	Inst Trans	-	Short Ratio	1.66	Perf Half Y	-20.06%
Book/sh	-1.62	P/B	-	EPS next Y	31.63%	ROA	-189.51%	Short Interest	0.35M	Perf Year	-44.39%
Cash/sh	0.13	P/C	20.21	EPS next 5Y	-	ROE	-1928.18%	52W Range	1.53 - 4.75	Perf YTD	-43.97%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-6.40%	ROI	-	52W High	-46.73%	Beta	0.85
Dividend TTM	-	Quick Ratio	0.58	Sales past 5Y	257.57%	Gross Margin	79.42%	52W Low	65.37%	ATR (14)	0.13
Dividend Ex-Date	-	Current Ratio	0.59	EPS Y/Y TTM	-10.55%	Oper. Margin	-668.86%	RSI (14)	42.56	Volatility	3.40% 4.89%
Employees	123	Debt/Eq	-	Sales Y/Y TTM	17.91%	Profit Margin	-666.91%	Recom	1.22	Target Price	11.93
Option/Short	No / Yes	LT Debt/Eq	-	EPS Q/Q	-	Payout	-	Rel Volume	0.02	Prev Close	2.59
Sales Surprise	-	EPS Surprise	20.67%	Sales Q/Q	-	Earnings	Sep 25 AMC	Avg Volume	211.08K	Price	2.53
SMA20	-4.53%	SMA50	0.60%	SMA200	-12.05%	Trades		Volume	5,120	Change	-2.31%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-12-24	Initiated	UBS	Neutral	$3
Oct-27-23	Initiated	Canaccord Genuity	Buy	$12
May-31-23	Initiated	ROTH MKM	Buy	$11
May-19-23	Upgrade	Societe Generale	Sell → Buy
Mar-17-23	Initiated	Stifel	Buy	$27
Nov-15-22	Downgrade	Societe Generale	Buy → Sell
Mar-08-21	Downgrade	Societe Generale	Buy → Sell
Aug-05-20	Initiated	ROTH Capital	Buy
Aug-04-20	Initiated	Stifel	Buy	$18
Aug-04-20	Initiated	Guggenheim	Buy	$26

Nov-21-24 04:00PM	Inventiva reports 2024 Third Quarter Financial Information (GlobeNewswire)
Nov-20-24 04:00PM	Statement of total voting rights and shares forming the companys share capital as of November 4, 2024 (GlobeNewswire)
04:00PM	Combined General Meeting of December 11, 2024 - Availability of the preparatory documents (GlobeNewswire)
Nov-15-24 04:00PM	Inventiva will present data from the final analysis of the Phase 2 study evaluating the combination of lanifibranor with empagliflozin in patients with MASH and T2D at the AASLD The Liver Meeting late-breaker session (GlobeNewswire)
Oct-30-24 04:00PM	Inventiva announces the positive recommendation of the fifth DMC of the NATiV3 Phase 3 clinical trial with lanifibranor in patients with MASH (GlobeNewswire)
08:30AM	Loading…
Oct-21-24 08:30AM	Inventiva announces a late breaker abstract from LEGEND, Phase 2 trial, evaluating lanifibranor in combination with empagliflozin in MASH at the AASLD The Liver Meeting 2024 (GlobeNewswire)
Oct-14-24 01:45PM	Inventiva announces the availability of a prospectus in connection with its financing through the issuance of ordinary shares and pre-funded warrants (GlobeNewswire) +41.27%
02:35AM	Inventiva announces Filing of 2024 Half-Year Report Conditions for Accessing or Consulting the Report (GlobeNewswire)
02:30AM	Inventiva announces financing of up to 348 million to advance the NATiV3 Phase 3 MASH study (GlobeNewswire)
Sep-25-24 04:00PM	Inventiva provides a corporate update and reports its unaudited 2024 first-half financial results (GlobeNewswire) -17.32%
Jul-31-24 04:00PM	Inventiva Reports Preliminary 2024 First-Half Financial Information (GlobeNewswire)
Jul-25-24 04:00PM	Inventiva secures a new patent in Japan, expanding the IP protection of its lead product candidate lanifibranor (GlobeNewswire)
Jul-19-24 11:30AM	Half-Year Review of Inventiva's Liquidity Contract with Kepler Cheuvreux (GlobeNewswire)
Jul-18-24 02:30AM	Inventiva announces a 20.1 million issuance of royalty certificates (GlobeNewswire)
Jul-05-24 04:00PM	Inventiva provides an update on its NATiV3 clinical program evaluating lanifibranor in patients with MASH/NASH and its financial position (GlobeNewswire) -10.85%
04:05PM	Loading…
Jun-21-24 04:05PM	Description of the Share Repurchase Program Authorised by the Ordinary General Meeting of 20 June 2024 (GlobeNewswire) -8.25%
04:00PM	Results of the votes of the Combined Shareholders' General Meeting of June 20, 2024 (GlobeNewswire)
Jun-18-24 09:35AM	Down -27.95% in 4 Weeks, Here's Why You Should You Buy the Dip in Inventiva (IVA) (Zacks)
May-30-24 02:30AM	Statement of total voting rights and shares forming the companys share capital as of May 13, 2024 (GlobeNewswire)
02:30AM	Combined General Meeting of June 20, 2024 - Availability of the preparatory documents (GlobeNewswire)
May-22-24 04:00PM	Inventiva announces two scientific presentations at the EASL International Liver Congress 2024 (GlobeNewswire)
May-21-24 04:00PM	Inventiva reports 2024 First Quarter Financial Information and provides a corporate update (GlobeNewswire)
May-16-24 04:00PM	Inventiva announces the positive recommendation of the fourth DMC of the NATiV3 Phase III clinical trial with lanifibranor in patients with MASH/NASH (GlobeNewswire)
May-13-24 04:08PM	Why Is Inventiva's Stock Trading Higher on Monday? (Benzinga) +5.33%
02:30AM	Inventiva announces the publication in Nature Communications of additional results from NATIVE Phase IIb clinical trial demonstrating improvement of markers of cardiometabolic health in patients with MASH/NASH treated with lanifibranor (GlobeNewswire)
Apr-03-24 04:00PM	Inventiva announces filing of its 2023 Universal Registration Document and 2023 Annual Report on Form 20-F (GlobeNewswire)
Apr-01-24 02:17PM	Inventiva S.A. (NASDAQ:IVA) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-28-24 03:00AM	Inventiva announces the nomination of Andre Turenne as Director (GlobeNewswire) -5.24%
Mar-27-24 04:00PM	Inventiva reports its 2023 full-year results (GlobeNewswire)
Mar-22-24 04:00PM	Inventiva announces the schedule of publication and presentation of its 2023 Full-Year Financial Results (GlobeNewswire)
04:00PM	Loading…
Mar-18-24 04:00PM	Inventiva announces positive results from the Phase II, LEGEND, Proof-of-Concept study combining lanifibranor with empagliflozin in patients with MASH/NASH and T2D (GlobeNewswire) -20.87%
Mar-13-24 04:00PM	Inventiva to present the results of LEGEND Phase IIa combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and T2D (GlobeNewswire)
Mar-07-24 04:00PM	Inventiva announces that screening in the NATiV3, Phase III, clinical trial evaluating lanifibranor in NASH has resumed (GlobeNewswire) +6.77%
Feb-16-24 05:46AM	Inventiva pauses phase 3 MASH study over patient's raised liver enzymes (FierceBiotech.com) -15.99%
Feb-15-24 04:35PM	Inventiva reports preliminary 2023 fiscal year financial Information and provides an update on its clinical trial NATiV3 (GlobeNewswire)
Jan-24-24 04:15PM	Half-Year Review of Inventiva's Liquidity Contract with Kepler Cheuvreux (GlobeNewswire)
Jan-10-24 04:00PM	Inventiva draws down the second tranche of 25 million under existing Finance Contract with the European Investment Bank (GlobeNewswire)
Dec-20-23 04:00PM	Inventiva announces the randomization of the first patient in China in the NATiV3 clinical trial and provides an update on its clinical development program (GlobeNewswire) -5.62%
Dec-04-23 04:05PM	Inventiva announces the positive recommendation of the third DMC of the Phase III clinical trial with lanifibranor in patients with NASH (GlobeNewswire)
Nov-21-23 04:00PM	Inventiva reports 2023 Third Quarter Financial Information (GlobeNewswire)
Nov-06-23 04:00PM	Inventiva announces a late breaker abstract and two additional abstracts on its lead compound, lanifibranor, at the AASLD The Liver Meeting 2023 (GlobeNewswire) +6.22%
Oct-27-23 10:01AM	Roblox upgraded, Bristol Myers downgraded: Wall Street's top analyst calls (The Fly)
Sep-28-23 04:00PM	Inventiva reports its 2023 first-half financial results and provides a corporate update (GlobeNewswire)
Sep-20-23 04:00PM	Inventiva and Hepalys Pharma, Inc. announce exclusive licensing agreement to develop and commercialize lanifibranor in Japan and South Korea (GlobeNewswire) +9.40%
Aug-31-23 01:30AM	Inventiva announces a financing of approximately 35.7 million from new and existing investors, consisting of a 30.6 million reserved capital increase and a 5.1 million issuance of royalty certificates (GlobeNewswire)
Jul-27-23 04:33PM	Correction: Inventiva Reports Preliminary 2023 First-Half Financial Information¹ and Business update (GlobeNewswire)
04:00PM	Inventiva Reports Preliminary 2023 First-Half Financial Information¹ and Business update (GlobeNewswire)
Jun-24-23 02:00AM	Inventiva announces the presentation of a scientific abstract at the 83rd Scientific Sessions of the American Diabetes Association (GlobeNewswire)
Jun-13-23 05:00PM	Inventiva announces positive topline results from the investigator-initiated Phase II clinical trial evaluating lanifibranor in patients with T2D and NAFLD (GlobeNewswire) +6.54%
Jun-08-23 02:30AM	Inventiva and Echosens launch joint initiative to increase NASH awareness and access to screening for at-risk patients (GlobeNewswire) -5.29%
Jun-07-23 04:00PM	Inventiva announces five scientific presentations at the EASL International Liver Congress 2023 (GlobeNewswire)
May-26-23 04:00PM	Results of the votes of the Combined Shareholders General Meeting of May 25, 2023 (GlobeNewswire) +7.45%
May-25-23 04:00PM	Inventiva announces that its partner Sino Biopharm received IND approval from the NMPA to initiate clinical trial with lanifibranor in China (GlobeNewswire) -6.00%
09:50AM	Description of the Share Repurchase Program Authorised by the Ordinary General Meeting of 25 May 2023 (GlobeNewswire)
May-16-23 04:00PM	Inventiva reports 2023 First Quarter Financial Information¹ and provides a corporate update (GlobeNewswire) -5.56%
May-04-23 02:31AM	Statement of total voting rights and shares forming the companys share capital as of April 17, 2023 (GlobeNewswire) +11.58%
02:30AM	Combined General Meeting of May 25, 2023. Availability of the preparatory documents (GlobeNewswire)
Apr-09-23 07:34PM	Inventiva S.A. (NASDAQ:IVA) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-30-23 08:19AM	Inventiva announces filing of its 2022 Universal Registration Document and 2022 Annual Report on Form 20-F (GlobeNewswire) -7.71%
Mar-29-23 04:00PM	Inventiva reports its 2022 full-year results (GlobeNewswire)
Mar-23-23 05:00PM	Inventiva announces the schedule of publication and presentation of its 2022 Full-Year Financial Results (GlobeNewswire)
Feb-14-23 05:00PM	Correction: Inventiva reports preliminary financial results for Full-Year 2022¹ (GlobeNewswire)
04:00PM	Inventiva reports preliminary financial results for Full-Year 2022¹ (GlobeNewswire)
Jan-30-23 04:00PM	Half-Year Review of Inventivas Liquidity Contract with Kepler Cheuvreux (GlobeNewswire)
Jan-26-23 02:00AM	Results of the votes of the Combined Shareholders General Meeting of January 25, 2023 (GlobeNewswire)
Jan-04-23 04:00PM	Inventiva announces changes to the clinical development of lanifibranor, including plans for a new Phase III trial in patients with NASH and compensated cirrhosis (GlobeNewswire) -7.84%
Jan-03-23 02:35AM	Statement of total voting rights and shares forming the companys share capital as of December 19, 2022 (GlobeNewswire) +11.43%
02:30AM	Combined General Meeting of January 25, 2023 - Availability of the preparatory documents (GlobeNewswire)
Dec-12-22 02:30AM	Inventiva draws down 25 million tranche under Finance Contract with the European Investment Bank (GlobeNewswire)
Nov-28-22 04:00PM	Inventiva secures a new patent expanding the IP protection of its lead product candidate lanifibranor in the US (GlobeNewswire) +10.93%
Nov-21-22 04:00PM	Inventiva announces a new Director of the Board of Directors (GlobeNewswire) -12.07%
Nov-10-22 04:00PM	Inventiva reports 2022 Third Quarter Financial Information¹ (GlobeNewswire) +8.36%
Oct-31-22 07:58AM	Take the Zacks Approach to Beat the Market: Caterpillar, Amgen, Inventiva in Focus (Zacks) -21.58%
07:50AM	After 10 Years Of Collaboration, AbbVie Discontinues Inventiva-Partnered Psoriasis Candidate (Benzinga)
03:00AM	Inventiva provides an update on the development of cedirogant by AbbVie (GlobeNewswire)
Oct-21-22 04:00PM	Inventiva announces a scientific presentation at the AASLD The Liver Meeting® 2022 (GlobeNewswire) +8.47% -7.81%
Sep-26-22 01:37PM	Inventiva's NASH Pact In China Represents 'Financially Prudent Pathway,' Says This Analyst (Benzinga)
Sep-22-22 07:27AM	Inventiva Inks Licensing Pact With China-Based Sino Biopharm For NASH Candidate In Greater China (Benzinga)
02:30AM	Inventiva reports its 2022 first-half financial results and provides a corporate update (GlobeNewswire)
Sep-21-22 04:40PM	Inventiva and Sino Biopharm announce licensing and collaboration agreement to develop and commercialize lanifibranor in Greater China (GlobeNewswire)
Sep-08-22 09:35AM	Here's Why Inventiva S.A. Sponsored ADR (IVA) is Poised for a Turnaround After Losing 18.4% in 4 Weeks (Zacks)
Sep-07-22 04:00PM	Inventiva announces the schedule of publication and presentation of its 2022 Half-Year Financial Results (GlobeNewswire) -9.09%
Jul-28-22 04:00PM	Inventiva Reports 2022 First-Half Financial Information¹ (GlobeNewswire)
Jul-21-22 12:00PM	Half-Year Review of Inventivas Liquidity Contract with Kepler Cheuvreux (GlobeNewswire)
Jul-07-22 04:00PM	Inventiva announces the screening of the first patient in LEGEND, a Phase IIa combination trial with lanifibranor and empagliflozin in patients with NASH and T2D (GlobeNewswire) +9.78%
Jul-04-22 12:45PM	Update on Inventiva's cash position and on the finance documentation with the European Investment Bank (GlobeNewswire)
Jun-16-22 04:00PM	Inventiva to host a webcast with Key Opinion Leaders following the EASL International Liver Congress 2022 (GlobeNewswire)
Jun-15-22 09:55AM	Here's Why Inventiva S.A. Sponsored ADR (IVA) Could be Great Choice for a Bottom Fisher (Zacks) -8.57%
Jun-09-22 04:00PM	Inventiva announces three scientific presentations at the EASL International Liver Congress 2022 (GlobeNewswire)
Jun-07-22 04:00PM	Inventiva joins the Euronext Tech Leaders segment (GlobeNewswire)
Jun-03-22 04:00PM	Inventiva announces the presentation of a scientific abstract at the 82nd Scientific Sessions of the American Diabetes Association (GlobeNewswire)
May-23-22 04:00PM	Inventiva announces participation at several investors conferences in May and June 2022 (GlobeNewswire)
May-20-22 04:00PM	Results of the votes of the Combined Shareholders Meeting of May 19, 2022 (GlobeNewswire)
May-19-22 04:00PM	Description of the Share Repurchase Program Authorised by the Ordinary General Meeting of 19 May 2022 (GlobeNewswire)
May-16-22 04:00PM	Inventiva reports 2022 First Quarter Financial Information and provides clinical development update (GlobeNewswire) +5.08%
12:24PM	Inventiva Raises 50M Debt Financing To Fund Its Lead Program In NASH Patients (Benzinga)
02:00AM	Inventiva secures a 50 million credit facility from the European Investment Bank (GlobeNewswire)
Apr-28-22 10:35AM	Statement of total voting rights and shares forming the companys share capital as of April 11, 2022 (GlobeNewswire)
10:30AM	Combined General Meeting of May 19, 2022 - Availability of the preparatory documents (GlobeNewswire)
Apr-07-22 04:00PM	Inventiva announces the presentation of a scientific abstract at the next International Conference on Fatty Liver (GlobeNewswire)

Inventiva SA is a clinical-stage biopharmaceutical company, which focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis, or NASH, and other diseases with significant unmet medical need. It owns an in-house drug-discovery platform that develops internal oncology and fibrosis discovery pipeline with approaches centered on transcription factors, epigenetics targets, and nuclear receptors. The company was founded by Pierre Broqua and Frederic Cren on October 27, 2011 and is headquartered in Daix, France.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

IVA

Inventiva ADR

Upgrade your FINVIZ experience